BBI Insider Trading Activity and SEC Form 4 Filings
BBI insider trading summary
No open-market insider purchases or sales of Brickell Biotech, Inc. (BBI) have been reported on SEC Form 4 in the past 12 months.
Latest BBI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jul 26, 2021 | Reginald L Hardy | Chairman of the Board | Buy | $67K (100,000 @ $0.67) |
| Jul 23, 2021 | Reginald L Hardy | Chairman of the Board | Buy | $66K (100,000 @ $0.66) |
| Jul 23, 2021 | David R. McAvoy | General Counsel and CCO | Buy | $12K (18,124 @ $0.67) |
| May 19, 2021 | Deepak Chadha | Chief Research & Dev. Officer | Buy | $10K (12,500 @ $0.83) |
| May 18, 2021 | Deepak Chadha | Chief Research & Dev. Officer | Buy | $2K (2,700 @ $0.82) |
| May 17, 2021 | Andrew D Sklawer | COO and Secretary | Buy | $12K (15,375 @ $0.80) |
| May 17, 2021 | David R. McAvoy | General Counsel and CCO | Buy | $15K (18,622 @ $0.80) |
| May 17, 2021 | David R. McAvoy | General Counsel and CCO | Buy | $6K (7,980 @ $0.80) |
| Mar 15, 2021 | Robert Busard Brown | Chief Executive Officer | Buy | $118K (100,000 @ $1.18) |
| Sep 18, 2020 | David R. McAvoy | General Counsel and CCO | Buy | $14K (16,526 @ $0.83) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.